CLINICAL TRIAL

A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)

A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-06-30
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Sunstone Medical

Watch author

Topics and keywords

psilocybin PTSD Clinical Trial Safety Clinical Trial Post Traumatic Stress Disorder PTSD Psilocybin 25 mg Psilocybin-assisted therapy RECRUITING

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress DisorderClinicalTrials.gov · 2026-05-21 Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New MexicoFrontiers in Public Health · 2026-06-16 Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept TrialClinicalTrials.gov · 2026-03-03 Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSDBMJ Open · 2023-04-30 A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-06-04 Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatmentEClinicalMedicine · 2025-11-30 Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.Unknown journal · 2025-11-06 Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trialJournal of Psychopharmacology · 2025-08-28